Bausch + Lomb Receives FDA Approval of Lumify

Bausch + Lomb announced that the U.S. Food and Drug Administration (FDA) has approved Lumify (brimonidine tartrate ophthalmic solution 0.025 per cent) as the first and only over-the-counter (OTC) eye drop developed with low-dose brimonidine tartrate for the treatment of ocular redness. Brimonidine, which was first approved by the FDA in 1996 for intraocular pressure (IOP) reduction in glaucoma patients, is available at higher doses in prescription eyecare products.

“With today’s approval of Lumify, consumers have a new and unique treatment option to relieve red, irritated eyes,” said Joseph C. Papa, chairman and CEO of Valeant. “Lumify is the first and only OTC eye drop with low-dose brimonidine, which has been clinically proven to be safe and effective since its initial approval as a prescription medication in 1996. We expect Lumify will be available for purchase at major retailers in the second quarter of 2018”.

Top